Vertex Pharmaceuticals

VRTX · NASDAQ

$514.65+$12.70 (+2.53%)TodayMarket closed · Oct 20, 4:05 PM ET

Prev close $501.95

Latest news

Press releaseOct 20, 4:05 PM ETBusiness Wire
Vertex Appoints Daniel Brennan to its Board of Directors
Press releaseOct 9, 1:15 PM ETBusiness Wire
Vertex to Present New Data on ALYFTREK® at the North American Cystic Fibrosis Conference
Press releaseOct 7, 4:00 PM ETBusiness Wire
Vertex to Announce Third Quarter 2026 Financial Results November 2nd
NewsOct 5, 3:00 PM ETPiero Cingari
Nasdaq 100 Records Have Rarely Been This Narrow, 55 Stocks Are Still Below 50-Day Average
NewsSep 22, 1:55 PM ETVandana Singh
Vertex Touts Encouraging Data From 'Underappreciated' Kidney Drug
Press releaseSep 22, 8:00 AM ETBusiness Wire
Vertex Announces Positive Results From Phase 2b AMPLIFIED Study of Inaxaplin in Additional Populations of People With APOL1-Mediated Kidney Disease (AMKD) and Completion of Enrollment in the Phase 2/3 AMPLITUDE Trial
Press releaseSep 15, 7:30 AM ETBusiness Wire
Vertex Partners With World Champion Skier Lindsey Vonn to Raise Awareness of JOURNAVX®, a Non-Opioid Medicine Approved for the Treatment of Moderate-to-Severe Acute Pain
Press releaseSep 8, 9:00 AM ETGlobe Newswire
Replacing Insulin Cells Works. Keeping The Cells Alive Is the Trick
Press releaseSep 1, 9:03 AM ETBusiness Wire
Vertex Completes Acquisition of Crinetics Pharmaceuticals and Announces Expansion of Executive Leadership Team
Press releaseAug 26, 4:00 PM ETBusiness Wire
Vertex to Participate in Upcoming September Investor Conferences
NewsAug 21, 8:19 AM ETAvi Kapoor
Uber, ServiceNow And A Health Care Stock On CNBC’s ‘Final Trades’
Press releaseAug 17, 12:57 PM ETBusiness Wire
Crinetics Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Crinetics Pharmaceuticals, Inc. - CRNX
Press releaseAug 3, 4:05 PM ETGlobe Newswire
Crinetics Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
NewsAug 3, 4:01 PM ET
Vertex Pharmaceuticals Q2 Adj. EPS $4.73, Inline, Sales $3.334B Beat $3.232B Estimate
Press releaseAug 3, 4:01 PM ETBusiness Wire
Vertex Reports Second Quarter 2026 Financial Results
NewsAug 3, 2:27 AM ETAvi Kapoor
Tyson Foods, Marriott And 3 Stocks To Watch Heading Into Monday
NewsAug 3, 2:21 AM ETAvi Kapoor
Nasdaq Jumps 1% as Amazon Shares Surge: Investor Sentiment Improves, But Greed Index Remains in 'Fear' Zone
Press releaseJul 29, 7:00 AM ETBusiness Wire
AbCellera Announces Collaboration with Vertex to Discover Multispecific T-Cell Engagers for Autoimmune Diseases and Other Conditions
NewsJul 21, 3:52 PM ETPiero Cingari
These 7 Small Caps Are on Fire as the Second Half Begins: Here’s Why
Press releaseJul 21, 9:00 AM ETPRNewswire
A Diabetes Therapy Just Locked In Its Cell Supplier, and the Race to End Insulin Injections Is Heating Up
NewsJul 9, 7:45 AM ETAvi Kapoor
Nvidia, Vertex Pharmaceuticals And More On CNBC’s ‘Final Trades’
Press releaseJul 8, 12:33 PM ETBusiness Wire
Crinetics Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Crinetics Pharmaceuticals, Inc. - CRNX
Press releaseJul 8, 9:00 AM ETPRNewswire
The Longevity Protein Race Reaches Manufacturing: One Microcap Just Completed A GMP Master Cell Bank For Its Anti-Aging Klotho Therapy
Press releaseJul 7, 4:00 PM ETBusiness Wire
Vertex to Announce Second Quarter 2026 Financial Results on August 3rd
NewsJul 7, 8:24 AM ETVandana Singh
Vertex Sees Over $5 Billion Peak Sales Potential From Crinetics Assets
NewsJul 6, 4:30 PM ETAdam Eckert
Crinetics Pharmaceuticals Stock Doubles After The Close: Here's Why
Press releaseJul 6, 4:04 PM ETBusiness Wire
Vertex to Acquire Crinetics Pharmaceuticals
NewsJul 2, 8:33 AM ETVandana Singh
Vertex Says Casgevy Label Expansion Opens Treatment to 5,500 More Us Children
NewsJul 2, 3:09 AM ET
Reported Earlier, Vertex Wins FDA Approval Expanding CASGEVY Use To Children As Young As 2 With Severe Sickle Cell Disease Or Beta Thalassemia
Press releaseJul 1, 7:58 PM ETBusiness Wire
Vertex Announces US FDA Approval for Expanded Use of CASGEVY® for the Treatment of People Ages 2 Years and Older With Sickle Cell Disease or Transfusion-Dependent Beta Thalassemia
NewsJul 1, 5:35 PM ET
FDA Approves First Gene Therapy for Young Children with Sickle Cell Disease; The FDA Granted The Approval To Vertex Pharmaceuticals
NewsJun 30, 7:50 AM ETAvi Kapoor
IBM, Verizon, Corning And A Health Care Stock On CNBC’s ‘Final Trades’
NewsJun 11, 12:20 PM ETVandana Singh
Vertex Says Pediatric CASGEVY Data Show Consistent Benefits In Rare Blood Disorders
Press releaseJun 11, 2:01 AM ETBusiness Wire
Vertex Presents New Data on CASGEVY®, Including First European Presentation of Data in Children Ages 5–11, at the European Hematology Association Congress and Announces Additional Global Regulatory Submissions
Press releaseJun 5, 12:00 PM ETBusiness Wire
Vertex Presents New Data on ALYFTREK® at European Cystic Fibrosis Conference
NewsNov 3, 2:23 PM ETAvi Kapoor
Vertex Pharmaceuticals Likely To Report Higher Q3 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
NewsOct 3, 8:23 AM ETAvi Kapoor
ServiceNow, Vertex Pharmaceuticals And More: CNBC's 'Final Trades'
NewsOct 2, 2:48 PM ETAvi Kapoor
Apple To Rally Around 17%? Here Are 10 Top Analyst Forecasts For Thursday

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Vertex Appoints Daniel Brennan to its Board of Directors

Vertex to Present New Data on ALYFTREK® at the North American Cystic Fibrosis Conference

Vertex to Announce Third Quarter 2026 Financial Results November 2nd

Nasdaq 100 Records Have Rarely Been This Narrow, 55 Stocks Are Still Below 50-Day Average

Vertex Touts Encouraging Data From 'Underappreciated' Kidney Drug

Vertex Announces Positive Results From Phase 2b AMPLIFIED Study of Inaxaplin in Additional Populations of People With APOL1-Mediated Kidney Disease (AMKD) and Completion of Enrollment in the Phase 2/3 AMPLITUDE Trial

Vertex Partners With World Champion Skier Lindsey Vonn to Raise Awareness of JOURNAVX®, a Non-Opioid Medicine Approved for the Treatment of Moderate-to-Severe Acute Pain

Replacing Insulin Cells Works. Keeping The Cells Alive Is the Trick

Vertex Completes Acquisition of Crinetics Pharmaceuticals and Announces Expansion of Executive Leadership Team

Vertex to Participate in Upcoming September Investor Conferences

Uber, ServiceNow And A Health Care Stock On CNBC’s ‘Final Trades’

Crinetics Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Crinetics Pharmaceuticals, Inc. - CRNX

Crinetics Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update

Vertex Pharmaceuticals Q2 Adj. EPS $4.73, Inline, Sales $3.334B Beat $3.232B Estimate

Vertex Reports Second Quarter 2026 Financial Results

Tyson Foods, Marriott And 3 Stocks To Watch Heading Into Monday

Nasdaq Jumps 1% as Amazon Shares Surge: Investor Sentiment Improves, But Greed Index Remains in 'Fear' Zone

AbCellera Announces Collaboration with Vertex to Discover Multispecific T-Cell Engagers for Autoimmune Diseases and Other Conditions

These 7 Small Caps Are on Fire as the Second Half Begins: Here’s Why

A Diabetes Therapy Just Locked In Its Cell Supplier, and the Race to End Insulin Injections Is Heating Up

Nvidia, Vertex Pharmaceuticals And More On CNBC’s ‘Final Trades’

Crinetics Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Crinetics Pharmaceuticals, Inc. - CRNX

The Longevity Protein Race Reaches Manufacturing: One Microcap Just Completed A GMP Master Cell Bank For Its Anti-Aging Klotho Therapy

Vertex to Announce Second Quarter 2026 Financial Results on August 3rd

Vertex Sees Over $5 Billion Peak Sales Potential From Crinetics Assets

Crinetics Pharmaceuticals Stock Doubles After The Close: Here's Why

Vertex to Acquire Crinetics Pharmaceuticals

Vertex Says Casgevy Label Expansion Opens Treatment to 5,500 More Us Children

Reported Earlier, Vertex Wins FDA Approval Expanding CASGEVY Use To Children As Young As 2 With Severe Sickle Cell Disease Or Beta Thalassemia

Vertex Announces US FDA Approval for Expanded Use of CASGEVY® for the Treatment of People Ages 2 Years and Older With Sickle Cell Disease or Transfusion-Dependent Beta Thalassemia

FDA Approves First Gene Therapy for Young Children with Sickle Cell Disease; The FDA Granted The Approval To Vertex Pharmaceuticals

IBM, Verizon, Corning And A Health Care Stock On CNBC’s ‘Final Trades’

Vertex Says Pediatric CASGEVY Data Show Consistent Benefits In Rare Blood Disorders

Vertex Presents New Data on CASGEVY®, Including First European Presentation of Data in Children Ages 5–11, at the European Hematology Association Congress and Announces Additional Global Regulatory Submissions

Vertex Presents New Data on ALYFTREK® at European Cystic Fibrosis Conference

Vertex Pharmaceuticals Likely To Report Higher Q3 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

ServiceNow, Vertex Pharmaceuticals And More: CNBC's 'Final Trades'

Apple To Rally Around 17%? Here Are 10 Top Analyst Forecasts For Thursday